ARIEL2 Trial: Hopes in Optimizing Predictor of Response

ARIEL2 Trial: Hopes in Optimizing Predictor of Response

User Photo
SGO2017

3 years
636 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Elizabeth Swisher, MD of University of Washington Medical Center discusses her hopes in the ARIEL2 Trial in helping to optimize predictor of response for patients with not only ovarian cancer, but other cancers as well. She states that ovarian cancer is the leading factor in the field of PARP inhibitors and what is learned in ovarian cancer can be applicable to other cancers. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)s Annual Meeting on Womens Cancer® in National Harbor, MD.
Up Next Autoplay
User Photo